Assessing active immune pathways in NSCLC - JTO and JCO CRR

Assessing active immune pathways in NSCLC – JTO and JCO CRR

JTO and JCO CRR shared a post on X:

“This study proposes a diagnostic shift from static biomarker quantification in pts with NSCLC to assessing active immune pathways in order to provide more precise ICI treatment. Ultimately, the results implicate a need for combination diagnostics and therapies.”

immune pathways

In situ detection of PD1–PD-L1 interactions as a functional predictor for response to immune checkpoint inhibition in NSCLC.

Authors: Amanda Lindberg et al.

Assessing active immune pathways in NSCLC - JTO and JCO CRR

Amanda Lindberg Artur Mezheyeuski cancer Carina Strell Cecilia Lindskog Erika Broström Hans Brunnström Hui Yu Jakob Friedrich Johan Botling Johan Isaksson Johanna Mattsson Klas Kärre Lars Muhl Louise Hellberg Lung cancer Max Backman Miklos Gulyas Neda Hekmati NSCLC OncoDaily Oncology Patrick Micke Rebecca Artursson